Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Increases In Galena Biopharma, Inc.'s (GALE) Institutional Investors Sparks Motley Fool Contributor Interest

|Includes: SELLAS Life Sciences Group, Inc. (SLS)

Galena Biopharma recently captured the attention of Motley Fool writer Ted Mayer who begins his opine by noting that investors can make wise investment decision by watching what institutional investors are doing. A watchful eye in this case, he says, starts by burrowing through SEC filings.

"Over the past few months, Galena Biopharma has gotten a lot of attention as it is developing several promising cancer treatments. Since the end of September, shares of the company have soared by more than 120%," writes Mayer. "This has increased the value of the company by more than $230 million. After looking at the recent investment fund filings, it looks like one of the big reasons for the move has been increased institutional investment. A few of the funds that have recently added shares are Barclays Global, Blackrock, Highland Capital Management, Bridgeway Capital Management, Dafna Capital Management, and UBS O'Connor."

To read the full article visit

The article recaps each fund's current stake in Galena, citing the company's advancements and outlook.

"This is an impressive list of investors that have upped their holdings. Additionally, the overall trend by institutions is impressive. During the most recent quarter, 18 new positions were initiated compared to just five closings. … This is likely due to both the company's recent progress and the potential that it has demonstrated," he writes.

Mayer also highlights Galena's breast cancer drug candidate, NeuVax, which is currently in a phase 3 PRESENT trial. He notes that current estimates are that upon FDA approval NeuVax could treat between 80,000 -120,000 new cases of breast cancer each year.

For more information, visit

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit